Project Grant R01CA299621
Award Date 3/25/26
Completion Date 2/28/31
Dollars Obligated $593K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Antonio, TX 78229, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) awarded a $164,000 Project Grant to The University of Texas MD Anderson Cancer Center, effective September 1, 2025, through August 31, 2027. This award supports research investigating the clonal determinants of platinum/PARP inhibitor (PARPi) cross-resistance in high-grade serous ovarian cancer (HGSOC). The research utilizes a novel somatic mosaic genetically-engineered mouse model...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $653,967 Project Grant to The University of Texas MD Anderson Cancer Center on March 16, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop novel therapeutic strategies targeting PPP2R1A mutations in gynecological cancers. The research deliverables focus on investigating the mechanistic basis by which PPP2R1A-mutated cancer cells demonstrate selective sensitivity to KAT6A (lysine acetyltransferase...
- Federal Project Grant Award Summary The National Cancer Institute awarded The University of Texas Health Science Center at San Antonio a $609,846 Project Grant effective April 1, 2026, through March 31, 2031, under the Cancer Treatment Research program (CFDA 93.395). This award funds research targeting mucin-type O-glycosylation as a novel regulatory mechanism in epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC). The research addresses the critical clinical...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center a $420,400 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This award supports exploratory studies investigating cellular resistance mechanisms to second-generation MTA-cooperative PRMT5 inhibitors (MTA:PRMT5I) in MTAP-loss tumors. The research addresses a critical clinical challenge whereby 40-60% of patients...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $627,371 project grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), awarded on June 23, 2025, with an expected completion date of May 31, 2030. This award supports research focused on overcoming treatment resistance in estrogen receptor-positive (ER+) breast cancer through targeted degradation of cyclin-dependent kinases 4 and 6 (CDK4/6). The...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Alabama a $631,621 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an integrated top-down proteomics and phosphoproteomics platform for analyzing patient-derived ovarian cancer spheroids. The award, effective August 13, 2025, through July 31, 2028, supports the creation of personalized intact proteome maps that characterize disease states and identify markers...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Grant Award Summary The University of Texas at Austin received a $668,878 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on April 3, 2026, with a completion date of March 31, 2031. This award supports the development of a novel antibody-drug conjugate (ADC) therapeutic platform targeting CD44 variant 9 (CD44V9) for advanced and treatment-resistant breast cancer. The research aims to overcome current limitations in...
- Federal Project Grant Award Summary The University of Texas Health Science Center at Houston received a $393,872 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective August 1, 2025 through July 31, 2027. The award supports research and development of therapeutic antibody-drug conjugates (ADCs) targeting leucine-rich repeat containing G protein-coupled receptor 5 (LGR5) and the receptor tyrosine kinase MET to overcome tumor...
- Federal Grant Award Summary The National Cancer Institute awarded a $404,972 Project Grant to The University of Texas Health Science Center at San Antonio under the Cancer Biology Research program (CFDA 93.396) for a two-year project period beginning August 1, 2025 and concluding July 31, 2027. This award supports fundamental research investigating ribosomal ribonucleic acid (rRNA) modification, ribosome composition, and specialized translation mechanisms in glioblastoma, the most common and...